However, the results presented in this work showing that inhibition of TBK1/IKKε leads to massively enhanced IL‐17‐induced signaling in both human and murine cell lines argue against potential therapeutic targeting of TBK1/IKKε kinase activity in treatment of IL‐17 mediated autoimmune diseases. The gene discussed is IL17A; the disease is autoimmune disease.